Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Riluzole · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Riluzole | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of Huntington's disease and CAG repeat length of 36 or more * UHDRS Motor score of at least 5 points * UHDRS TFC score of at least 8 points, i.e. patients must be independently ambulatory and must not require nursing care * Females require a negative blood p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |
Riluzole is a small molecule being studied for the treatment of Huntington Disease. It is currently in Phase 3 clinical development as an investigational therapy. The drug has been evaluated in a completed Phase 3 trial with 537 participants, though it is not yet approved for this condition.
Riluzole is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker SNY. Sanofi is conducting clinical research to evaluate the drug's potential in treating Huntington Disease.
Riluzole is in Phase 3 clinical development for Huntington Disease. It has completed one Phase 3 trial, which enrolled 537 participants. The drug remains investigational and has not been approved for this indication.
Riluzole has been studied in a completed Phase 3 clinical trial identified as NCT00277602, titled "Riluzole in Huntington's Disease." This trial enrolled 537 participants with Huntington Disease and was a randomized, double-blind study.
Riluzole is not FDA approved for Huntington Disease. It is an investigational drug currently in Phase 3 clinical development. The completed Phase 3 trial, NCT00277602, evaluated the drug in 537 participants, but approval status has not been established.